Want to join the conversation?
$MDT's 1Q16 sales jumped 70%, helped by a 14% growth in Cardiac and Vascular Group, 13% growth in Restorative Therapies Group and a 7% growth in Diabetes Group. This also includes addition of $2.46Bil of revenue from Minimally Invasive Therapies Group due to the acquisition of Covidien.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.
$VZ down more than 2% after a disappointing third quarter. A lot of uncertainty on the Yahoo deal too.